Our results on successful use of CD276.V-CAR T in CD276high RMS tumors are in line with the results obtained with other CAR constructs targeting CD276 in preclinical studies against several types of tumors: 276.8αHD/TM.28CSD.BBCSD.3ζ against glioblastoma [78]; 276.MG.8αHD/TM.BBCSD.3ζ against medulloblastoma [36], neuroblastoma [36, 79], osteosarcoma [36], and Ewing sarcoma [36]; 276.8H9S3.3.8α.28TM.BBCSD.3ζ against gastric cancer [80]; and 276.8αHD.28TM.28CSD.3ζ and 276.8αHD/TM.BBCSD.3ζ against esophagus squamous cell carcinoma [81]. This evidence concerns the gene CD276 and glioblastoma.